Article citationsMore >>

Abdo A. Elfiky. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences. 2020 248, 117477.

has been cited by the following article:

Article

Docking Analysis of 07 Anti-HCV Drugs with COVID-19 Main Protease PDB ID: 6LU7

1Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee, India

2Department of Pharmaceutical Sciences, J. S. University, Shikohabad, India


American Journal of Pharmacological Sciences. 2020, Vol. 8 No. 2, 21-25
DOI: 10.12691/ajps-8-2-1
Copyright © 2020 Science and Education Publishing

Cite this paper:
Ajeet , Babita Aggarwal, Santosh Kumar Verma, Ajeet Singh. Docking Analysis of 07 Anti-HCV Drugs with COVID-19 Main Protease PDB ID: 6LU7. American Journal of Pharmacological Sciences. 2020; 8(2):21-25. doi: 10.12691/ajps-8-2-1.

Correspondence to: Ajeet , Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee, India. Email: ajeet_pharma111@rediffmail.com

Abstract

07 anti-HCV drugs have been processed and observed by docking analysis for understanding the binding patteren of drugs with COVID-19 main protease PDB ID: 6LU7 for any possibilities of protease inhibition. For docking analysis PyRx- Python Prescription 0.8 was used. This analysis reveals that the essential amino acids involved in binding of anti-HCV drugs to COVID-19 main protease PDB ID: 6LU7 are Threonine (THR), Cysteine (CYS), Histidine (HIS), Methionine (MET) and Proline (PRO). After docking analysis it was observed that Ledipasvir may be act as COVID-19 main protease inhibitor despite of being anti-HCV and may further be used in the treatment of COVID-19 infection after having proper clinical proofs.

Keywords